表紙
市場調査レポート

世界の硬直性脊椎炎市場

Global Ankylosing Spondylitis Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 322806
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界の硬直性脊椎炎市場 Global Ankylosing Spondylitis Market 2015-2019
出版日: 2015年01月07日 ページ情報: 英文 102 Pages
概要

硬直性脊椎炎は脊椎関節症の亜型で、脊椎の炎症による痛みとそれにより脊椎の動きや胸部拡大が制限されるものです。原因は分かっていませんが、HLA-B27遺伝子が重要な役割を担っています。世界の硬直性脊椎炎市場は2014〜2019年にかけCAGR5.05%で拡大すると予測されています。

当レポートでは、世界の硬直性脊椎炎市場の概要と市場の動向、将来予測、様々な治療薬別の収益動向、地域別動向、およびベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 レポートの範囲

第4章 市場調査方法

第5章 イントロダクション

第6章 疾患概要

  • 疾患の理解
  • 硬直性脊椎炎の原因
  • 病態生理学
  • 疫学
  • 診断
  • 治療と管理
  • 経済的負担

第7章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 作用機序別市場セグメンテーション

  • TNF阻害剤
  • COX阻害剤
  • その他

第9章 分子タイプ別市場セグメンテーション

  • 生物製剤
  • 小分子

第10章 投与経路別市場セグメンテーション

  • 経口
  • 非経口

第11章 剤形別市場セグメンテーション

  • 固形
  • 液体

第12章 地域別セグメンテーション

第13章 購買基準

第14章 市場成長促進因子

第15章 促進因子とその影響

第16章 市場の課題

第17章 促進因子と課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー環境

  • 競合シナリオ
  • ベンダー分析
  • その他の注目すべきベンダー

第21章 パイプラインポートフォリオ

第22章 主要ベンダー分析

  • AbbVie Inc.
  • Amgen
  • Janssen Pharmaceuticals
  • Merck
  • Pfizer

第23章 当シリーズの他のレポート

図表

目次
Product Code: IRTNTR5050

About Ankylosing Spondylitis

Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.

TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:

  • TNF Inhibitors
  • COX Inhibitors
  • Others

On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:

  • Biologics
  • Small Molecules

On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:

  • Oral
  • Parenteral

In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:

  • Solid
  • Liquid

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed.

TechNavio's report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Merck & Co.
  • Pfizer

Other Prominent Vendors

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Celltrion
  • Eisai
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Novartis
  • Otsuka Pharmaceutical
  • Regeneron Pharmaceuticals
  • Sanofi
  • Shanghai Pharmaceuticals
  • UCB

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • Threat from Patent Expiry
  • For a full, detailed list, view our report

Market Trend

  • Market Dominance by Biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Causes of Ankylosing Spondylitis
  • 06.3. Pathophysiology
  • 06.4. Epidemiology
  • 06.5. Diagnosis
  • 06.6. Treatment and Management
    • 06.6.1. Analgesics
    • 06.6.2. Corticosteroids
    • 06.6.3. DMARDs
    • 06.6.4. Biologics
    • 06.6.5. Physiotherapy
    • 06.6.6. Surgery
  • 06.7. Economic Burden

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Mechanism of Action

  • 08.1. TNF Inhibitors
  • 08.2. COX Inhibitors
  • 08.3. Others

09. Market Segmentation by Type of Molecule

  • 09.1. Biologics
  • 09.2. Small Molecules

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Forms

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Competitive Assessment of the Top Drugs for Ankylosing Spondylitis
    • 20.2.2. Abbvie
    • 20.2.3. Janssen Pharmaceuticals
    • 20.2.4. Amgen
    • 20.2.5. Pfizer
    • 20.2.6. Merck
  • 20.3. Other and Future Prominent Vendors

21. Pipeline Portfolio

22. Key Vendor Analysis

  • 22.1. AbbVie Inc.
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Product Segmentation by Revenue 2013
    • 22.1.4. Product Segmentation by Revenue 2012 and 2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Developments
    • 22.1.8. SWOT Analysis
  • 22.2. Amgen
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation by Revenue 2013
    • 22.2.4. Product Portfolio by Revenue 2013
    • 22.2.5. Business Segmentation by Revenue 2012 and 2013
    • 22.2.6. Geographical Segmentation by Revenue 2013
    • 22.2.7. Business Strategy
    • 22.2.8. Recent Developments
    • 22.2.9. SWOT Analysis
  • 22.3. Janssen Pharmaceuticals
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Recent Developments
    • 22.3.4. SWOT Analysis
  • 22.4. Merck
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
  • 22.5. Pfizer
    • 22.5.1. Key Facts
    • 22.5.2. Business Overview
    • 22.5.3. Business Segmentation by Revenue 2013
    • 22.5.4. Business Segmentation by Revenue 2012 and 2013
    • 22.5.5. Geographical Segmentation by Revenue
    • 22.5.6. Business Strategy
    • 22.5.7. Key Developments
    • 22.5.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
  • Exhibit 3: Snapshot of Ankylosing Spondylitis
  • Exhibit 4: Diagnosis of Ankylosing Spondylitis
  • Exhibit 5: Treatment and Management of Ankylosing Spondylitis
  • Exhibit 6: Snapshot of the Economic Burden of Ankylosing Spondylitis
  • Exhibit 7: Snapshot of the Global Ankylosing Spondylitis Market
  • Exhibit 8: Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
  • Exhibit 9: Drivers and Challenges of Global Ankylosing Spondylitis Market
  • Exhibit 10: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action
  • Exhibit 11: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action 2014
  • Exhibit 12: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule
  • Exhibit 13: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule 2014
  • Exhibit 14: Global Ankylosing Spondylitis Market Segmentation by Route of Administration
  • Exhibit 15: Global Ankylosing Spondylitis Market Segmentation by Route of Administration 2014
  • Exhibit 16: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms
  • Exhibit 17: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms 2014
  • Exhibit 18: Global Ankylosing Spondylitis Market by Geographical Segmentation 2014
  • Exhibit 19: Buying Criteria of the Global Ankylosing Spondylitis Market
  • Exhibit 20: Drivers and their Impact on the Key Customer Category of the Global Ankylosing Spondylitis Market
  • Exhibit 21: Drivers and Their Geography-wise Impact on the Global Ankylosing Spondylitis Market
  • Exhibit 22: YoY Sales Comparison of Top Drugs used for Ankylosing Spondylitis 2010-2013 (US$ million)
  • Exhibit 23: Revenue Share of the Top Drugs used for Ankylosing Spondylitis 2010-2013
  • Exhibit 24: Abbvie: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 25: YoY Global Sales of Humira 2008-2013 (US$ million)
  • Exhibit 26: Janssen: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 27: YoY Sales of Remicade 2005-2013 (US$ million)
  • Exhibit 28: YoY Sales of Simponi 2010-2013 (US$ million)
  • Exhibit 29: Amgen: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 30: YoY Sales of Enbrel (In US and Canada) 2005-2013 (US$ million)
  • Exhibit 31: YoY Sales of Enbrel In US 2005-2013 (US$ million)
  • Exhibit 32: YoY Sales of Enbrel In Canada 2005-2013 (US$ million)
  • Exhibit 33: Region-wise Sales Comparison of Enbrel 2005-2013 (US$ million)
  • Exhibit 34: Pfizer: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 35: YoY Sales of Enbrel (Outside US and Canada) 2009-2013 (US$ million)
  • Exhibit 36: YoY Sales of Enbrel (Outside US and Canada) 2008-2013 (US$ million)
  • Exhibit 37: Merck: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 38: YoY Sales of Remicade 2005-2013 (US$ million)
  • Exhibit 39: YoY Sales of Simponi 2010-2013 (US$ million)
  • Exhibit 40: AbbVie Inc.: Product Segmentation by Revenue 2013
  • Exhibit 41: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 42: AbbVie Inc.: Sales by Geography 2013
  • Exhibit 43: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 44: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 45: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 46: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 47: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 48: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 49: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 50: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 51: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 52: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top